Biotech ETFs Surge After Invitae Acquires ArcherDX

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic information company’s offering lineup and growth outlook. Among the best performing non-leveraged...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.